BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 20938663)

  • 1. Iron overload in MDS-pathophysiology, diagnosis, and complications.
    Gattermann N; Rachmilewitz EA
    Ann Hematol; 2011 Jan; 90(1):1-10. PubMed ID: 20938663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Current understanding of iron overload hazard in patients with myelodysplastic syndrome].
    Song LX; Su JY; Zhang Z; Chang CK
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):484-8. PubMed ID: 23628060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registry.
    Neukirchen J; Fox F; Kündgen A; Nachtkamp K; Strupp C; Haas R; Germing U; Gattermann N
    Leuk Res; 2012 Aug; 36(8):1067-70. PubMed ID: 22564985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron overload in myelodysplastic syndromes: a Canadian consensus guideline.
    Wells RA; Leber B; Buckstein R; Lipton JH; Hasegawa W; Grewal K; Yee K; Olney HJ; Larratt L; Vickars L; Tinmouth A
    Leuk Res; 2008 Sep; 32(9):1338-53. PubMed ID: 18405971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
    Delforge M; Selleslag D; Triffet A; Mineur P; Bries G; Graux C; Trullemans F; MacDonald K; Abraham I; Pluymers W; Ravoet C
    Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathophysiological and clinical aspects of iron chelation therapy in MDS.
    Gattermann N
    Curr Pharm Des; 2012; 18(22):3222-34. PubMed ID: 22571702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The deleterious effects of iron overload in patients with myelodysplastic syndromes.
    Dreyfus F
    Blood Rev; 2008 Dec; 22 Suppl 2():S29-34. PubMed ID: 19059054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes.
    Jabbour E; Kantarjian HM; Koller C; Taher A
    Cancer; 2008 Mar; 112(5):1089-95. PubMed ID: 18186499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
    Gattermann N
    Leuk Res; 2007 Dec; 31 Suppl 3():S10-5. PubMed ID: 18037413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes.
    Malcovati L
    Leuk Res; 2007 Dec; 31 Suppl 3():S2-6. PubMed ID: 18037415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in the understanding of iron overload in sideroblastic myelodysplastic syndrome.
    Cuijpers ML; Raymakers RA; Mackenzie MA; de Witte TJ; Swinkels DW
    Br J Haematol; 2010 May; 149(3):322-33. PubMed ID: 20067561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron overload and chelation therapy in myelodysplastic syndromes.
    Temraz S; Santini V; Musallam K; Taher A
    Crit Rev Oncol Hematol; 2014 Jul; 91(1):64-73. PubMed ID: 24529413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of iron overload in myelodysplastic syndromes.
    Fenaux P; Rose C
    Blood Rev; 2009 Dec; 23 Suppl 1():S15-9. PubMed ID: 20116635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy.
    Leitch HA
    Leuk Res; 2007 Dec; 31 Suppl 3():S7-9. PubMed ID: 18037416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate.
    Imran F; Phatak P
    Expert Rev Hematol; 2017 Jan; 10(1):53-64. PubMed ID: 27923273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of transfusion-related iron overload in patients with myelodysplastic syndromes.
    Shah J; Kurtin SE; Arnold L; Lindroos-Kolqvist P; Tinsley S
    Clin J Oncol Nurs; 2012 Jun; 16 Suppl():37-46. PubMed ID: 22641283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron overload in myelodysplastic syndromes (MDS).
    Gattermann N
    Int J Hematol; 2018 Jan; 107(1):55-63. PubMed ID: 29177643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2 technique.
    Konen E; Ghoti H; Goitein O; Winder A; Kushnir T; Eshet Y; Rachmilewitz E
    Am J Hematol; 2007 Nov; 82(11):1013-6. PubMed ID: 17654681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox.
    Kikuchi S; Kobune M; Iyama S; Sato T; Murase K; Kawano Y; Takada K; Ono K; Kaneko Y; Miyanishi K; Sato Y; Hayashi T; Takimoto R; Kato J
    Free Radic Biol Med; 2012 Aug; 53(4):643-8. PubMed ID: 22705364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron overload in myelodysplastic syndromes: diagnosis and management.
    List AF
    Cancer Control; 2010 Jan; 17 Suppl():2-8. PubMed ID: 20125080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.